A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

Pertuzumab is widely used for the treatment of HER2  + breast cancer. But its safety in the real world should be continuously monitored. So, we evaluated the safety of pertuzumab by pharmacovigilance analyze ba...

Source: BMC Clinical Pharmacology - November 13, 2023 Category: Drugs & Pharmacology Authors: Shu-peng Zou, Hai-yun Yang, Meng-ling Ouyang, Qian Cheng, Xuan Shi and Ming-hui Sun Tags: Research Source Type: research